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Aims Epidemiological studies report an inverse association between plant-derived dietary a-linolenic acid (ALA) and
cardiovascular events. However, little is known about the mechanism of this protection. We assessed the cellular
and molecular mechanisms of dietary ALA (flaxseed) on atherosclerosis in a mouse model.
Methods
and results
Eight-week-old male apolipoprotein E knockout (ApoE2/2) mice were fed a 0.21 % (w/w) cholesterol diet for 16
weeks containing either a high ALA [7.3 % (w/w); n ¼ 10] or low ALA content [0.03 % (w/w); n ¼ 10]. Bioavailability,
chain elongation, and fatty acid metabolism were measured by gas chromatography of tissue lysates and urine. Plaques
were assessed using immunohistochemistry. T cell proliferation was investigated in primary murine CD3-positive
lymphocytes. T cell differentiation and activation was assessed by expression analyses of interferon-g, interleukin-
4, and tumour necrosis factor a (TNFa) using quantitative PCR and ELISA. Dietary ALA increased aortic tissue
levels of ALA as well as of the n23 long chain fatty acids (LC n23 FA) eicosapentaenoic acid, docosapentaenoic
acid, and docosahexaenoic acid. The high ALA diet reduced plaque area by 50% and decreased plaque T cell
content as well as expression of vascular cell adhesion molecule-1 and TNFa. Both dietary ALA and direct ALA
exposure restricted T cell proliferation, differentiation, and inflammatory activity. Dietary ALA shifted prostaglandin
and isoprostane formation towards 3-series compounds, potentially contributing to the atheroprotective effects of
ALA.
Conclusion Dietary ALA diminishes experimental atherogenesis and restricts T cell-driven inflammation, thus providing the
proof-of-principle that plant-derived ALA may provide a valuable alternative to marine LC n23 FA.
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Keywords a-Linolenic acid † Atherosclerosis † Inflammation † Polyunsaturated fatty acids
* Corresponding author. Tel: +41 44 635 64 67, Fax: +41 44 635 68 27, Email: christian.matter@access.uzh.ch
† These authors contributed equally to this work.
Published on behalf of the European Society of Cardiology. All rights reserved. & The Author 2011. For permissions please email: journals.permissions@oup.com.
The online version of this article has been published under an open access model. Users are entitled to use, reproduce, disseminate, or display the open access version of this article
for non-commercial purposes provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the
original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this
must be clearly indicated. For commercial re-use, please contact journals.permissions@oup.com
European Heart Journal (2011) 32, 2573–2584
doi:10.1093/eurheartj/ehq501
Introduction
Atherosclerosis is a chronic inflammatory disease of the vascula-
ture, which eventually leads to myocardial infarction or stroke.1
The majority of acute myocardial infarctions can be attributed to
modifiable cardiovascular risk factors such as exercise and diet.2
Epidemiological studies have shown an inverse correlation between
consumption of dietary long chain n23 fatty acids (LC n23 FA) and
cardiovascular events.3–5 Increased intake of the marine-derived eico-
sapentaenoic acid (EPA) and docosapentaenoic acid (DPA) exert anti-
arrhythmic,6 lipid-lowering,7 antihypertensive, and potentially
anti-thrombotic effects.8,9 These effects may result in part from a
modulation of immunological functions. Indeed, in vitro EPA inhibits
cytokine-induced cell surface expression of MHC II, as well as inflam-
matory cytokine expression itself of antigen-presenting cells.10,11
Moreover, dietary fish oil decreases natural killer cell and cytotoxic
T cell activity decreasing the cell-mediated immune response.10
These findings set the rationale for international health organizations
to adapt nutritional guidelines in favour of an increased intake of
marine-derived LC n23 FA.12 However, the availability of n23 FA
from marine origin remains restricted in many countries due to
expensive supply, cultural preference, unfavourable geography, and
the depletion of menhaden, a marine forage fish (Clupeidae) at the
bottom of the food chain capable to generate large quantities of
n23 FA from algae.13 Therefore, a-linolenic acid (ALA), a plant-
derived n23 FA, may provide a valuable cardioprotective alternative
to marine n23 FA.
a-Linolenic acid is an essential intermediate (as opposed to long-)
chain n23 fatty acid, found in high concentrations in vegetable oils
such as flaxseed oil, where it accounts for over 50% of the total
fatty acid content.14 Being a precursor of LC n23 FA, ALA is partially
converted into EPA and DPA in the body.15 Data about the efficiency
of the conversion of ALA into its longer chain metabolite EPA remain
controversial, ranging from 0.05 to 8%.16–18 Recent epidemiological
studies report an inverse association between dietary ALA and
sudden cardiac death,6 acute myocardial infarction,13 and athero-
sclerotic plaque calcification.19 Moreover, in vitro studies20,21 allow
some insight into the beneficial effects of marine-derived n23 FA.
However, the mechanisms responsible for the potentially protective
phenomena upon supplementation of plant-derived n23 FA remain
insufficiently understood.
Given the growing epidemiological evidence suggesting ALA as
an effective and accessible cardioprotective nutritional supplement,
this study aims to investigate the cellular and molecular mechan-
isms of dietary ALA in a mouse model of atherosclerosis.
Methods
Detailed information about the Methods section is available in Sup-
plemental material online.
Animals and diet
Eight-week-old male C57/BL6 ApoE2/2 mice were fed a 0.21 % (w/w)
cholesterol diet for 16 weeks containing either a high ALA [7.3 %
(w/w), D06080702, Research Diets, USA; n ¼ 10] or a low ALA pro-
portion [0.03 % (w/w), D06080701, Research Diets; n ¼ 10]. All
animal experiments were approved by the local Ethics Committee.
Blood analyses
Mice were fasted over night before blood was drawn. Lipids were ana-
lysed using the reagents TR13421, TR22421 (Thermo Electron Clinical
Chemistry and Automation Systems, USA) and 994-75409 (Wako
Chemicals GmbH, Germany). The lipid distribution in plasma lipopro-
tein fractions was assessed by chromatography gel filtration.
Tissue processing
For en face analyses, thoraco-abdominal aortae were excised and
opened longitudinally. Plaques were visualized by fat staining. For his-
tological examination, cryosections were obtained. For biochemical
analyses, tissue was shock-frozen in liquid nitrogen.
Plaque quantification
Atherosclerotic plaques were analysed en face in thoraco-abdominal
aortae as described.22
Complementary analyses of plaque size and composition were per-
formed in serial longitudinal cryosections of the aortic arch as
described.23
Endothelial function and oxidative stress
Aortic rings were obtained and dose–response curves generated using
an isometric force transducer (MultiMyograph, DMT, Denmark) as
described.24
Key reactive oxygen species generating and scavenging enzymes
were assessed in aortic lysates by quantitative PCR (qPCR) and
western blot analyses as described below. Total and small molecule
antioxidant capacity of plasma was measured using the total antioxi-
dant capacity kit (Abcam) according to the manufacturer’s instructions.
The direct detection of aortic reactive oxygen species was performed
using electron spin resonance spectroscopy as described previously.25
Cytoplasmic reactive oxygen species in aortae were assessed using
dihydroethydine (Sigma, USA) stainings.
Immunohistochemistry and
immunofluorescence
Cryosections were blocked and stained using the following antibodies:
rat anti-mouse CD68, CD3, and vascular cell adhesion molecule 1
(VCAM-1; Serotec, UK), and goat anti-mouse tumour necrosis factor
a (TNFa; Santa Cruz, USA).
Lipid profiles
Tissue lipid profiles were analysed using gas– liquid chromatography of
fatty acid methyl esters26 after fractionation of lipid classes by solid-
phase extraction.
Urine analyses
Twenty-four-hour urines were collected using metabolic cages. Prosta-
glandins and isoprostanes (iPs) were extracted and quantified utilizing
liquid chromatography/mass spectrometry/mass spectrometry analyses
as described.27– 29 Metabolite levels were corrected for urinary
creatinine.
Cell culture
Splenocytes were harvested from ApoE2/2 mice and CD3- and
CD11c-positive cells were magnetically separated. Purity was assessed
by flow cytometry. CD3- and CD11c-positive lymphocytes were cul-
tured in supplemented RPMI-1640.
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Flow cytometry
Flow cytometry analyses were performed in a FACSCanto II using
FACSDiva software (both BD, Heidelberg, Germany). Results were
expressed in percentage positive cells or mean fluorescence intensity.
Functional in vitro assays
For proliferation assays CD3-positive lymphocytes were activated by
anti-CD3 and anti-CD28 antibody presentation (BD, USA) before
treatment with ALA (Cayman Chemical, USA) or vehicle (ethanol
0.1%, Sigma). Cells were incubated for 78 h including incorporation
of 3H-thymidine during the final 18 h. Thymidine incorporation was
measured using liquid scintillation. a-Linolenic acid-mediated cytotox-
icity was assessed by colorimetric quantification of lactate dehydrogen-
ase release. Expression analyses in CD11c-positive cells (FACS, qPCR,
ELISA) were performed in either stimulated or unstimulated cells.
A capture ELISA was used to quantify cytokine release in the super-
natant. For analysis of IL-4, IL-6, p40, IFNg, and TNFa, BD OptEIATM
ELISA Sets (BD, USA) were used.
RNA analyses
RNA isolation and reverse transcription were performed according to
standard protocols. Quantitative PCR was carried out in a Stratagene
Mx 3000 PTM machine (Stratagene, USA) using the Stratagene MxPro
sequence detection system and software. Expression was calculated
using the DDCT method. Relative gene expression was normalized to
murine 12S rRNA expression as an internal control.
Western blot analyses
Western blot analyses of aortic lysates were performed according to
standard protocols.
Statistics
Statistical analysis was performed using an unpaired two-tailed Student’s
t-test or one-way ANOVA with Dunnett’s correction where appropri-
ate. Significance was accepted at P, 0.05. Values are expressed as
mean+ SEM. Sample size was calculated with average values and stan-
dard deviations from previous experience (7.5+ 2.1 and 21.2+
12.6%). With an estimated effect size of 1.5, an a-error probability of
0.05, and a power of 0.80, the expected sample size was seven per
group. Calculations were performed in GraphPad PRISM 5.01 (GraphPad
Software Inc., USA) and G*Power 3.1 (Institute of Experimental Physi-
ology, University of Dusseldorf, Germany).30
Results
Dietary a-linolenic acid diminishes plaque
formation
To determine the effects of a diet enriched with ALA on athero-
sclerotic plaques, male ApoE2/2 mice were exposed to a 0.21 %
(w/w) cholesterol diet for 16 weeks containing either a high
concentration of ALA [7.3 % (w/w); n ¼ 10] or a low concen-
tration of ALA [0.3 % (w/w); n ¼ 10]. Dietary ALA was provided
as flaxseed oil, which was compensated for with cocoa butter in
the control diet (Table 1). Total fat, protein, and carbohydrate
contents were kept constant. To mimic a ‘western-type’ diet,
trans-fat content was 1.7 % (w/w) in both diets. Mice exposed to
a high ALA diet revealed a 50% decrease (P ¼ 0.014) in en face
thoraco-abdominal aortic plaque formation (Figure 1A)
and in plaques on serial longitudinal sections of the aortic arch
(P ¼ 0.016) (Figure 1B). Surprisingly, no difference in endothelial
function was observed between the two groups (see Supplemen-
tary material online, Figure S1A), which was paralleled by
unchanged levels of aortic reactive oxygen species (see Sup-
plementary material online, Figures S1B and S2) and total antioxi-
dant capacity in plasma (see Supplementary material online,
Figure S1C). Interestingly, we observed a slight increase in small
molecule antioxidant capacity (P ¼ 0.0044) in plasma from mice
of the intervention group (see Supplementary material online,
Figure S1C). Expression levels of endothelial nitric oxide synthase,
p47/phox, NOX1 (p22/phox), NOX2 (gp91/phox) as well as of
superoxide dismutase 1–3 in aortic lysates were unchanged (see
Supplementary material online, Figure S3).
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Table 1 Formulas of the high and the low ALA diet,
respectively
Low ALA High ALA
% (w/w) kcal% % (w/w) kcal%
Protein 20 17 20 17
Carbohydrate 50 43 50 43
Fat 21 40 21 40
kcal/g 4.68 4.68
Ingredient g kcal g kcal
Casein 195 780 195 780
DL-Methionine 3 12 3 12
Corn starch 50 200 50 200
Maltodextrin 10 100 400 100 400
Sucrose 341 1364 341 1364
Cellulose, BW200 50 0 50 0
Milk fat, anhydrous 0 0 0 0
Corn oil 10 90 10 90
Cocoa butter 137 1233 0 0
Flaxseed oil 0 0 137 1233
Primex shortening 63 567 63 567
Mineral mix S10001 35 0 35 0
Calcium carbonate 4 0 4 0
Vitamin mix V10001 10 40 10 40
Choline bitartrate 2 0 2 0
Cholesterol USP 2.1 0 2.1 0
Ethoxyquin 0.04 0 0.04 0
FD&C blue dye #1 0 0 0.05 0
FD&C yellow dye #5 0.05 0 0 0
Total 1002.14 4686 1002.14 4686
% (w/w) kcal% % (w/w) kcal%
C18:3 n23, ALA 0.03 0.06 7.3 13.90
n23 FA 0.08 0.15 7.15 13.62
n26 FA 16.38 3.12 3.61 6.88
n26/n23 20.73 0.51
Trans-fat 1.7 6.16 1.7 6.16
The source of a-linolenic acid (C18:3 n23, ALA) is flaxseed oil. The fat content in
the low ALA diet is compensated for by cocoa butter. The calories/weight and fat
including total cholesterol and trans-fat content of the two diets are identical.
Dietary a-linolenic acid, T cells, and atherogenesis 2575
Dietary a-linolenic acid restricts plaque
T cell content, tumour necrosis factor a,
and vascular cell adhesion molecule 1
expression
To investigate the effects of dietary ALA on plaque inflammation, we
performed immunohistochemical stainings for T cells (CD3) and
macrophages (CD68) (Figure 1A and B). We observed an 85%
decrease (P ¼ 0.0065) in T cell content in the interventiongroup com-
pared with the control group. The CD68-positive area remained
unchanged, suggesting that macrophage content did not differ
between the groups. Blood counts did not reveal any differences in cir-
culating monocytes or lymphocytes (see Supplementary material
online, Table S1C). Interestingly, dietary ALA reduced TNFa and
VCAM-1 expression in plaques (P ¼ 0.017 and P ¼ 0.016) (Figure 2C
and D), consistent with attenuation of endothelial activation, succes-
sive leucocyte adhesion, and subsequent intimal infiltration.
a-linolenic acid decreases T cell
differentiation, activation, and proliferation
Given the marked decrease in CD3-positive cells in the plaques of
the intervention group, we investigated the specific effects of ALA
on T cells in vivo and in vitro. Therefore, CD3-positive lymphocytes
from the two mouse groups were isolated from spleens and
interferon-g (IFNg) as well as interleukin-4 (IL-4) expression was
assessed by qPCR, as a surrogate for Th1 and Th2 differentiation,
respectively (Figure 3A and B). T cells of animals fed a high ALA diet
expressed less IL-4 (P ¼ 0.011), suggesting reduced differentiation
towards Th2 cells, whereas IFNg expression remained unchanged.
Dietary ALA reduced TNFa expression in T cells by 42% (P ¼
0.024) (Figure 3C). TNFa expression was also reduced in spleens
of animals exposed to a high ALA diet (P ¼ 0.0046) without
changing the amount of CD3-positive cells (Figure 3D and E).
TNFa expression colocalized with CD3-positive lymphocytes
(Figure 3F).
To substantiate these observations, we performed a dose–
response curve of ALA in cultured T cells using primary
CD3-positive cells isolated from ApoE2/2 mice fed a normal
diet. a-linolenic acid doses were chosen to reflect plasma levels
achieved upon dietary ALA intake.15 mRNA levels of IL-4, IFNg,
and TNFa dose-dependently decreased in response to ALA
(Figure 4A). These findings were confirmed at the protein level
using ELISAs specific for IL-4, IFNg, and TNFa (Figure 4D–F ) in
cell culture supernatants.
Figure 1 Dietary a-linolenic acid (ALA) decreases aortic plaque formation. Oil-red O stainings of atherosclerotic plaques in
thoraco-abdominal aortae (A) en face and (B) in longitudinal aortic arch sections of ApoE2/2 mice fed a high or low ALA diet (n ¼ 10
each). Scale bars ¼ 1 mm. *P, 0.05 compared with the low ALA group.
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Since the Th2 cytokine IL-4 is a potent mitogen, we tested the
effects of ALA on T cell proliferation. a-linolenic acid adminis-
tration dose-dependently decreased the proliferation of
CD3-positive lymphocytes from ApoE2/2 mice (Figure 4C). We
excluded cytotoxic effects of ALA treatment by measuring LDH
release in cell culture supernatants (Figure 4C).
In order to address putative effects of ALA on the cross-talk
between T cells and antigen-presenting cells, we determined
the expression of co-stimulatory factors in T cells and dendritic
cells isolated from ApoE2/2 mice. We investigated the contri-
bution of the B7 family (B7.1 and 2, L-ICOS, and ICOS) and
the TNF/TNF receptor family (CD40 and CD40L, as well as
CD137) as well as the secretion of IL-6 and IL-12. In dendritic
cells, we observed no regulation upon increasing concentrations
of ALA. In T cells, however, increasing doses of ALA led to
decreased expression of ICOS, CD40L, and CD137 as well as
IL12Rb2 at the mRNA level. At the protein level, though, no
difference was detected (see Supplementary material online,
Figures S3 and S4). These data suggest that co-stimulatory
pathways do not relevantly contribute to the observed
phenotype.
Dietary flaxseed enhances tissue levels of
a-linolenic acid and its n23 long chain
metabolites
To assess the efficiency of dietary ALA incorporation into target
tissues, we quantified ALA in tissue lysates (Table 2). a-Linolenic acid
tissue levels within the intervention group were markedly increased
ranging from an over 60-fold increase (P ¼ 0.024 × 10218) in
Figure 2 Dietary a-linolenic acid (ALA) reduces plaque T cell content, vascular cell adhesion molecule 1 (VCAM-1), and TNFa expression.
Immunohistochemical stainings of (A) CD3, (B) CD68, (C) TNFa, and (D) VCAM-1 in plaques of ApoE2/2 mice fed a high or low ALA diet
(n ¼ 10 each). Scale bars ¼ 50 mm (A and B) and 1 mm (C and D). *P, 0.05 and **P, 0.01 compared with the low ALA group.
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perirenal white adipose tissue (WAT) to an over 250-fold increase
(P ¼ 0.03 × 1028) in red blood cell (RBC) membranes.
Furthermore, we addressed the conversion of ALA to n23 FAs
by measuring EPA, DPA, and docosahexaenoic acid (DHA)
(Table 2). In animals receiving an ALA-enriched diet, tissue levels
of EPA were increased ranging from a 2.3-fold increase in perirenal
(P ¼ 0.019 × 1024) and subcutaneous WAT (P ¼ 0.097 × 1026)
to a 56-fold increase in RBC membranes (0.012 × 1029). Docosa-
pentaenoic acid levels within the intervention group were also
elevated between 1.8-fold in aortae and 56-fold in livers (P ¼
0.029 × 1029). The same phenomenon was observed with
regard to DHA being increased after dietary ALA by 1.8-fold in
RBC membranes (P ¼ 0.000019) and 4.6-fold in livers (P ¼
0.0016). These findings indicate that oral flaxseed is sufficient to
increase ALA tissue levels and that tissue conversion from ALA
to LC n23 FA (EPA, DPA, and DHA) is taking place.
Since n23 and n26 FA metabolisms are interdependent and
partially rely on the same mechanisms, we also quantified n26
FA. Arachidonic acid (AA), the n26 equivalent to EPA, was
decreased in tissues of animals fed an ALA-enriched diet, ranging
from 2.1-fold less in livers (P ¼ 0.0041) to 4.8-fold less in aortae.
These effects are reflected in the EPA/AA ratio and the total
n26/total n23 FA ratio, which were both reduced in all analysed
tissues.
Figure 3 Dietary a-linolenic acid (ALA) decreases differentiation and inflammatory activity of primary murine CD3-positive lymphocytes.
(A–C) CD3-positive cells were isolated from spleens of ApoE2/2 mice fed a high or low ALA diet (n ¼ 5 each). T cells were stimulated
and cultured for 48 h before harvesting. Gene expression was quantified by quantitative PCR. (D–F ) Spleens of ApoE2/2 mice fed a high
or low ALA diet (n ¼ 5 each) were harvested and stained for TNFa (red) and CD3 (green). ×200. *P, 0.05 and **P, 0.01 compared
with the low ALA group.
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Dietary a-linolenic acid induces a shift to
3-series prostanoids and isoprostanes
To assess the effects of dietary ALA on FA metabolism and sub-
sequent eicosanoid generation, we quantified urinary metabolites
of both n26- and n23-derived eicosanoids (Figure 5). Major
urinary metabolites of the 2-series prostaglandins E (PGEM), D
(PGDM), I (PGIM), and thromboxane B2 metabolite
31 were not
altered by the high ALA diet. These compounds mirror systemic
biosynthesis of the respective AA-derived 2-series prostanoids. In
contrast, a significant increase in the corresponding urinary
thromboxane A3 metabolite (TxB3M) was detected. This reflects
a shift towards 3-series prostanoid formation. Analyses of iPs,
free radical-catalysed prostanoid isomers, revealed a similar
striking shift towards 3-series products. These changes are sup-
ported by a marked decrease in the urinary TxB2M/TxB3M
and iP-2/iP-3 ratios in animals fed the ALA-rich diet (Figure 5B
and D).
Discussion
a-Linolenic acid is a plant-derived intermediate chain n23 fatty
acid and precursor of the marine-derived LC n23 FA EPA, DPA,
and DHA. Epidemiological studies report an inverse association
between dietary ALA and cardiovascular events.6,13,19 However,
little is known about the mechanisms of a putative
atheroprotection.
Figure 4 a-Linolenic acid (ALA) decreases differentiation, inflammatory activity, and proliferation of T cells in a dose-dependent manner.
CD3-positive cells were isolated form ApoE2/2 mice on a normal diet. (A and B) Cells were stimulated for 24 h before ALA was applied in
the doses indicated (1, 5, and 25 mM). After additional 24 h, supernatant and RNA were obtained and analysed by quantitative PCR (A) and
ELISA (B), respectively. (C ) CD3-positive lymphocytes were stimulated and ALA was applied. Proliferation was assessed by 3H-thymidine incor-
poration. Cytotoxicity was analysed by LDH quantification in cell culture supernatants. *P, 0.05 and **P, 0.01 compared with control
conditions.
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We demonstrate that dietary ALA diminishes plaque formation,
plaque T cell infiltration, as well as TNFa and VCAM-1 expression
using a mouse model of atherosclerosis. Dietary flaxseed increased
tissue levels of ALA, EPA, DPA, and DHA. Conversely, it reduced
AA in aortas and other tissues and increased urinary excretion of
3-series iPs and TxB3M. Both dietary ALA and direct ALA treatment
restricted T cell proliferation, differentiation, and inflammatory activity.
a-Linolenic acid was delivered in concentrations at the high and
low end of an achievable human dietary consumption. Although in
humans 3 g/day is sufficient to increase ALA plasma levels from
19.2 to 32.8 mM, up to 40 g/d have been administered and well tol-
erated.15 When designing the diets, we focused on equal energy
levels (fat, protein, and carbohydrate) in both diets. a-Linolenic
acid was provided as flaxseed and compensated in the control
diet using cocoa butter. Cocoa butter consists mainly of the satu-
rated fatty acids (SFA) palmitic and stearic acid as well as the
monounsaturated fatty acid oleic acid. In vivo and in vitro studies
report minimal effects of dietary SFA on inflammatory cells.15,32,33
Although the ALA content in the flaxseed-based diet was over
90-fold higher compared with the control diet, linoleic acid (LA), the
n26 equivalent of ALA, was also slightly increased in the intervention
diet. This diet composition translates into profoundly increased tissue
levels of ALA and total n23 fatty acids compared with only mildly
increased tissue levels of n26 fatty acids, respectively. As the metab-
olism of n26 and n23 fatty acids is strongly interdependent, the
dietary n26/n23 ratio confers more biological relevance than their
absolute values. This ratio positively correlates with the incidence of
cardiovascular events.34–36 Consistent with these findings, all analysed
tissues revealed a marked decrease in the n26/n23 ratio, paralleled by
a 50% reduction in plaque area upon dietary ALA. In all tissues
assessed, including aortic lysates, a marked increase in ALA was
observed. Thus, the diets used in this study provided high and low
ALA contents as natural food components, securing a high ALA bioa-
vailability in energetically matched diets.
a-Linolenic acid supplementation decreased atherosclerotic
plaque formation in ApoE2/2 mice, paralleled by a marked reduction
in TNFa-, subsequent VCAM-1 expression, and inflammatory
CD3-positive T cell infiltration. We observed no changes in macro-
phage content in ApoE2/2 mice, in contrast to another study per-
formed in LDL receptor-deficient mice.37 The decreased TNFa
expression throughout the plaque observed upon dietary ALA
could be attributed to T cells. Our in vitro studies showed a profound
effect of ALA on T cell activation and proliferation corroborating
previous data32 and a decelerated differentiation to the Th1 pheno-
type, thus conferring atheroprotective properties, such as contribut-
ing to reduced plaque destabilization as reported in patients with
acute coronary syndromes.38– 40
The observed reduction of T cell activity in response to ALA
matches other studies reporting reduced leucocyte TNFa
expression upon marine EPA or DHA administration.20,32 Without
differences in plasma lymphocyte counts, the diminished T cell pro-
liferation after ALA exposure may result from para- or autocrine
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Table 2 Oral flaxseed intake increases tissue levels of a-linolenic acid and long chain n23 fatty acids
% (w/w) FA Low ALA High ALA Low ALA High ALA Low ALA High ALA
Red blood cells Liver Aorta
ALA 0.01+0.002 2.54+0.1** 0.14+0.03 15.9+1.2** 0.2 18.5
C20 5n23 (EPA) 0.08+0.005 4.5+0.13** 0.1+0.01 2.9+0.6** n.d. 0.7
C22 5n23 (DPA) 0.31+0.01 3.9+0.13** 0.01+0.01 1.5+0.1* 0.28 0.5
C22 6n23 (DHA) 2.5+0.04 4.5+0.26** 0.7+0.07 3.2+0.7** 0.08 0.2
AA 14.1+0.2 3.0+0.06 2.7+0.3 1.3+0.3 2.4 0.5
AA/EPA 177.7+11.7 0.7+0.03** 25.1+2.3 0.4+0.03** n.d. 0.7
n26 28.0+0.3 19.0+0.9** 9.6+0.7 19.5+1.0** 11.3 18.0
n23 3.0+0.04 16.0+1.2** 1.0+0.08 25.2+0.8** 0.5 20.2
n26/n23 9.3+0.2 1.2+0.1** 9.4+0.4 0.8+0.03** 20.7 0.9
% (w/w) FA Periadvent. WAT Perirenal WAT Subcut. WAT
ALA 0.22+0.01 17.0+0.4** 0.3+0.022 18.6+0.6** 0.2+0.01 18.7+0.05**
C20 5n23 (EPA) 0.02+0.002 0.3+0.06** 0.03+0.002 0.07+0.004** 0.03+0.002 0.07+0.004**
C22 5n23 (DPA) 0.01+0.002 0.2+0.03** 0.01+0.003 0.09+0.01* 0.01+0.01 0.08+0.01**
C22 6n23 (DHA) 0.1+0.01 0.4+0.13** 0.02+0.01 0.07+0.01** 0.02+0.002 0.05+0.01**
AA 0.7+0.04 0.3+0.07** 0.13+0.01 0.04+0.005** 0.13+0.01 0.04+0.005**
AA/EPA 35.7+2.4 0.7+0.05** 4.2+0.38 0.4+0.09** 5.1+0.25 0.6+0.09**
n26 8.8+0.3 18.4+0.9** 7.4+0.1 19.0+0.4** 7.6+0.1 18.7+0.4**
n23 0.5+0.03 18.2+0.4** 0.3+0.07 19.0+0.6** 0.3+0.03 19.1+0.5**
n26/n23 23.6+1.0 1.0+0.04** 27.7+2.9 1.0+0.03** 29.1+1.7 0.98+0.04**
Red blood cells, liver, aorta, and white adipose tissue (WAT) of mice fed a high or low ALA diet were analysed by gas chromatography. All comparisons between the control and
intervention groups revealed significant differences. Aortic tissue samples were pooled for analyses.
*P, 0.01.
**P, 0.001.
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Figure 5 3-Series isoprostanes (iPs-3) and thromboxane B3 metabolite (TxB3M) are the chief metabolites of dietary a-linolenic acid (ALA).
(A) Eicosapentaenoic acid and arachidonic acid are either subject to radical-catalysed oxidation to isoprostanes or COX-mediated conversion
to prostanoids. (B) Urine obtained from ApoE2/2 mice fed a high or low ALA diet, respectively, were analysed for metabolites of polyunsa-
turated fatty acids; COX, cyclooxygenase; ROS, reactive oxygen species; LOX, lipoxygenase; iPs, isoprostanes; PNs, prostanoids; TxB2M, throm-
boxane B2 metabolite; TxB3M, thromboxane B3 metabolite; PGDM, 11,15-dioxo-9-hydroxy-2,3,4,5-tetranorprostan-1,20-dioic acid
(prostaglandin D2 metabolite); PGEM, 7a-hydroxy-5,11-diketotetranor-prostane-1,16-dioic acid (prostaglandin E2 metabolite); PGIM,
2,3-dinor-6-keto prostaglandin F1a (prostaglandin I2 metabolite). (C) Ratio of 2-series/3-series isoprostanes. (D) Ratio of thromboxane B2
metabolite/thromboxane B3 metabolite *P, 0.05, **P, 0.01, and ***P, 0.001.
Dietary a-linolenic acid, T cells, and atherogenesis 2581
effects of reduced IL-4 expression. These findings and the corre-
sponding local events may explain the marked reduction of plaque
T cells after ALA supplementation. Notably, expression analyses in
dendritic cells and T cells did not reveal a relevant contribution of
co-stimulatory pathways to the atheroprotective phenotype.
Neither did we observe a difference in endothelial function, in the
aortic content of reactive oxygen species, nor the aortic expression
of reactive oxygen species generating and scavenging enzymes. Inter-
estingly, plasma small molecule anti-oxidant capacity in the interven-
tion group was slightly increased. However, with small molecules
accounting for,30% of the total anti-oxidant capacity, the observed
difference was neither sufficient to alter the total anti-oxidant
capacity nor to change the absolute quantity of aortic reactive
oxygen species. These findings indicate that the reduction in athero-
sclerotic plaque formation upon dietary ALA is not mediated by
differential effects on oxidative stress.
a-Linolenic acid is an essential n23 fatty acid. Whether the
effects upon its consumption reflect the activity of ALA itself or
of its longer chain n23 fatty acid derivatives remains a matter of
debate.18 The conversion of ALA to EPA and DPA is well
known, whereas further conversion to DHA is limited in
mammals.17 Levels of EPA, DPA, and DHA were abundantly
increased in our mouse model when ALA was supplemented.
This was predominantly the case in circulating RBCs and the
liver, but also in white adipose and aortic tissue. In contrast to
other studies suggesting that the enzymes (desaturase) for this
process have been lost during early evolution,41,42 our results
imply a substantial degree of chain elongation, allowing a potential
indirect, eicosanoid-dependent effect. Indeed, we observed dimin-
ished AA in aortae paralleled by decreased plaque T cell counts
in mice fed a high ALA diet. Arachidonic acid constitutes the sub-
strate for both prostanoid/thromboxane and leucotriene synthesis.
Interestingly, previous publications highlight the role of AA-derived
leucotriene metabolites on T cell chemotaxis.43,44 Our tissue find-
ings corroborate these reports and suggest a link between
AA-derived eicosanoids and T cell-driven atherogenesis.
In parallel, our urinary analyses revealed a shift towards 3-series
prostanoid formation, most evident in the depressed TxB2M/
TxB3M ratio. There was a similar shift from n26- to
n23-derived iPs in mouse urine, reflected by the markedly
depressed iP2/iP3 ratio. The compounds measured in this study
are the most abundant urinary iPs identified, analogous isomers
of PGF2a and PGF3a, respectively.
28 This striking increase in the
iP-3 compound is consistent with the increased susceptibility to
peroxidation of n23 compared with n26 FAs. These findings
may be of mechanistic relevance as some 3-series analogues
such as TxA3 are less potent ligands at prostanoid receptors
than the corresponding AA-derived product.45 Given that
genetic deletion and pharmacological inhibition of the Tx receptor
(TP) decrease atherogenesis in mice and that iPs may act as inci-
dental agonists at the TP, this shift in product formation may con-
tribute to the impact of nutritional ALA on atherogenesis.46– 48
A second, indirect, EPA- and DHA-mediated mechanism contri-
buting to the observed atheroprotective phenotype may also lie
within reduced plasma cholesterol levels. By activating the
nuclear receptors LXRa and b, EPA and DHA have been reported
to inhibit intestinal cholesterol absorption.49 Indeed, we observed
reduced plasma cholesterol levels in the intervention group,
whereas plasma triglycerides and lipoprotein subfractions did not
differ. However, this effect was much less pronounced than the
marked reduction of CD3-positive lymphocytes within the athero-
sclerotic lesions of the intervention group.
Notably, we observed not only altered expression profiles in
T cells after long-term dietary ALA consistent with indirect
effects, but also after short-term ALA exposure in cell culture
experiments. These findings indicate direct effects, most likely inde-
pendent of lipid-derived mediators, i.e. eicosanoids. Taking into
account the marked decrease in plaque T cell content, differen-
tiation, inflammatory activity, and proliferation in response to
ALA, we propose that the interplay of both direct (e.g. TNFa
expression) and indirect (i.e. eicosanoid-dependent) mechanisms
mediate atheroprotection.
Some limitations of this study deserve to be mentioned. The effects
observed are based on a mouse model of atherosclerosis and extra-
polations to clinical practice have to be made with caution. Mice typi-
cally lack vulnerable plaques and differ in the time period needed for
plaque formation as well as in their genetic and lipid profile allowing
atherogenesis. Moreover, we used a high amount of dietary ALA that
may be difficult to widely apply in patients. We consider these limit-
ations to be minor as our goal was to provide a proof-of-principle. We
aimed to investigate the effects of dietary ALA on atherosclerosis and
investigate cellular and molecular aspects of this concept in a well-
characterized mouse model.
In conclusion, we provide evidence that plant-derived dietary ALA
diminishes plaque formation and restricts T cell-driven inflammation
in atherosclerotic mice. Given the limited availability of n23 FAs
from marine origin, ALA may provide a valuable atheroprotective
nutritional alternative. Interestingly, two most recent studies
provide more insight into this area: an elegant experimental study
identified the G protein-coupled receptor 120 (GPR120) in macro-
phages mediating broad anti-inflammatory effects and increased
insulin sensitivity in response to n23 FAs.50 The prospective
Alpha Omega Trial reported that a low-dose dietary supplemen-
tation of ALA did not significantly reduce major cardiovascular
events after myocardial infarction, but may be effective in distinct
patient subgroups.51 Thus, further investigation is needed in exper-
imental and clinical studies to determine the optimal dosing of ALA,
its key molecular mechanisms, and target patient populations.
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online.
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